Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 mai 2026 08h30 HE | Source: BioMedWire

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain...
12 mai 2026 08h30 HE | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
06 mai 2026 08h30 HE | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease

AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a late-stage clinical biopharmaceutical company focused...